Foundations
Here's a look at documents from U.S. foundations
Foundations
Featured Stories
Royal Marsden NHS Foundation Trust: Nearly One Third of Patients With Advanced Melanoma Saw Tumours Disappear Completely After Receiving TIL Therapy Plus Pembrolizumab Immunotherapy
LONDON, England, Oct. 24 (TNSxrep) -- The Royal Marsden National Health Service Foundation Trust issued the following news:
* * *
Nearly one third of patients with advanced melanoma saw tumours disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy
An early-stage clinical trial suggests combining two types of immunotherapy at the start of treatment, lifileucel TIL therapy and an immune checkpoint inhibitor, may lead to deep and long-lasting responses.
23 October 2026
Results from a clinical trial have revealed nearly one third (29.2 per cent) of patients with advanced ... Show Full Article LONDON, England, Oct. 24 (TNSxrep) -- The Royal Marsden National Health Service Foundation Trust issued the following news: * * * Nearly one third of patients with advanced melanoma saw tumours disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy An early-stage clinical trial suggests combining two types of immunotherapy at the start of treatment, lifileucel TIL therapy and an immune checkpoint inhibitor, may lead to deep and long-lasting responses. 23 October 2026 Results from a clinical trial have revealed nearly one third (29.2 per cent) of patients with advancedmelanoma saw their tumours disappear completely on scans after receiving lifileucel TIL therapy alongside an immune checkpoint inhibitor, pembrolizumab, as a first-line treatment.
In addition, approximately two thirds (62.5 per cent) of patients in the same group saw their tumours shrink significantly, with many experiencing substantial and long-lasting responses to the combined treatment.
These findings from the IOV-COM-202 clinical trial, an international, multicentre Phase II trial conducted at The Royal Marsden NHS Foundation Trust, were presented at the 2026 European Society for Medical Oncology Congress by Dr Andrew Furness, Consultant Medical Oncologist and Solid Tumour Cellular Therapy Lead at The Royal Marsden NHS Foundation Trust and Leader of the Cellular Therapy and Translational Immunology Group at The Institute of Cancer Research, London.
The findings suggest that introducing lifileucel earlier in the treatment pathway may improve outcomes for patients.
Combined approach of distinct immunotherapy types
In 2024, lifileucel became the first cellular therapy approved by the U.S. Food and Drug Administration (FDA) for solid tumours after the C-144-01 clinical trial demonstrated a response rate of 31.4 per cent in patients whose cancer had progressed following previous treatments. This study aimed to understand whether the therapy could deliver greater benefit when used earlier in the course of the disease.
Lifileucel and pembrolizumab are two distinct forms of cancer immunotherapy. Lifileucel is a tumour-infiltrating lymphocyte (TIL) therapy, which harnesses the power of a patient's immune system by extracting immune cells from a patient's tumour, multiplying them in a laboratory, and returning them to the bloodstream, allowing them to more effectively recognise and attack cancer cells.
Pembrolizumab is an immune checkpoint inhibitor, a type of drug that blocks proteins which normally restrain the immune system, allowing a patient's T cells to better detect and attack cancer cells.
Pembrolizumab is a proven first-line treatment for many patients with advanced melanoma. However, a significant fraction of patients do not experience long-lasting benefit. Lifileucel has been shown to offer a second chance at long-lasting cancer control when standard immunotherapies, including pembrolizumab, are no longer effective. The IOV-COM-202 trial sought to determine the potential benefit of combining both therapies as a first-line treatment.
Most trial participants experienced significant tumour shrinkage
The trial selected 27 patients with advanced melanoma and treated them with a combination of pembrolizumab and lifileucel. Patients first received chemotherapy to prepare the body for treatment, before receiving the cell infusion and a short course of interleukin-2, a drug that boosts immune cell activity and is given after TIL therapy to help the infused cells grow and attack the cancer.
Of the 27 patients treated, 24 were included in the trial's main analysis.
After a median follow-up period of 26.9 months, researchers found that 15 of the 24 patients (62.5 per cent) experienced significant tumour shrinkage, with approximately one third (29.2 per cent) of patients seeing their tumours disappear completely on scans.
The median duration of response had not yet been reached more than two years after the trial began, meaning that many patients who responded to treatment were still benefiting from it at the time of analysis.
Among the 15 patients whose cancer responded to treatment, 13 maintained their response for at least 12 months, while 10 remained in complete or partial response at their most recent assessment.
No additional side effects with combined approach
Median progression-free survival, which is the length of time before a patient's cancer returned or progressed, was 19.8 months. Median overall survival, the length of time within the trial that a patient remained alive, had not yet been reached after 50.9 months of follow-up.
Patients experienced no additional side effects beyond those associated with the individual treatments.
Researchers are now evaluating this approach in TILVANCE-301, an international Phase III trial comparing lifileucel plus pembrolizumab with pembrolizumab alone in patients with advanced melanoma, for which Dr Andrew Furness is the UK National Chief Investigator.
"Immune checkpoint inhibitors like pembrolizumab have transformed outcomes for patients with advanced melanoma, with around half of patients achieving long-term cancer control. However, for those that do not derive long-term benefit, novel therapeutic options are urgently required," explains Dr Andrew Furness.
"Our findings suggest that adding TIL therapy to first-line pembrolizumab can produce deep and durable responses. Larger studies will now help us understand which patients are most likely to benefit from this combination and how it can best be used alongside existing immunotherapies."
"My tumours disappeared after TIL therapy and pembrolizumab"
After being diagnosed with melanoma in 2024, Paul Jenner, 59, a former ballet dancer and landscape construction company owner from London, was referred to The Royal Marsden after tests showed his cancer had spread beyond the original site to nearby lymph nodes.
Paul joined the IOV-COM-202 trial and received TIL therapy and pembrolizumab in August 2024. His cancer is currently in remission.
"It's amazing, really, that your own cells can be used in this way and used to heal you," said Paul.
"Before I had the treatment, there was spread to my lung, there was a growth on my back and there were a couple of other areas doctors were keeping an eye on. These all disappeared after the TIL therapy and pembrolizumab.
"The Royal Marsden is an incredible place and there are such lovely people working there, from everyone on the wards to the research staff who talked me through the trial. You can't help but feel grateful to have the chance to have something like TIL therapy. I don't know where I'd be without it."
The IOV-COM-202 study is funded by Iovance Biotherapeutics, Inc. Solid tumour cellular therapy research at The Royal Marsden is funded by supporters of The Royal Marsden Cancer Charity including our charity partner Nationwide, and The National Institute for Health and Care Research (NIHR) Biomedical Research Centre at The Royal Marsden and the ICR.
Dr Andrew Furness' role is part-funded by The Royal Marsden Cancer Charity.
* * *
Original text here: https://www.royalmarsden.nhs.uk/news-and-events/news/nearly-one-third-patients-advanced-melanoma-saw-tumours-disappear-completely
* * *
Nearly one third of patients with advanced melanoma saw tumours disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy
An early-stage clinical trial suggests combining two types of immunotherapy at the start of treatment, lifileucel TIL therapy and an immune checkpoint inhibitor, may lead to deep and long-lasting responses.
23 October 2026
Results from a clinical trial have revealed nearly one third (29.2 per cent) of patients with advanced ... Show Full Article LONDON, England, Oct. 24 (TNSxrep) -- The Royal Marsden National Health Service Foundation Trust issued the following news: * * * Nearly one third of patients with advanced melanoma saw tumours disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy An early-stage clinical trial suggests combining two types of immunotherapy at the start of treatment, lifileucel TIL therapy and an immune checkpoint inhibitor, may lead to deep and long-lasting responses. 23 October 2026 Results from a clinical trial have revealed nearly one third (29.2 per cent) of patients with advancedmelanoma saw their tumours disappear completely on scans after receiving lifileucel TIL therapy alongside an immune checkpoint inhibitor, pembrolizumab, as a first-line treatment.
In addition, approximately two thirds (62.5 per cent) of patients in the same group saw their tumours shrink significantly, with many experiencing substantial and long-lasting responses to the combined treatment.
These findings from the IOV-COM-202 clinical trial, an international, multicentre Phase II trial conducted at The Royal Marsden NHS Foundation Trust, were presented at the 2026 European Society for Medical Oncology Congress by Dr Andrew Furness, Consultant Medical Oncologist and Solid Tumour Cellular Therapy Lead at The Royal Marsden NHS Foundation Trust and Leader of the Cellular Therapy and Translational Immunology Group at The Institute of Cancer Research, London.
The findings suggest that introducing lifileucel earlier in the treatment pathway may improve outcomes for patients.
Combined approach of distinct immunotherapy types
In 2024, lifileucel became the first cellular therapy approved by the U.S. Food and Drug Administration (FDA) for solid tumours after the C-144-01 clinical trial demonstrated a response rate of 31.4 per cent in patients whose cancer had progressed following previous treatments. This study aimed to understand whether the therapy could deliver greater benefit when used earlier in the course of the disease.
Lifileucel and pembrolizumab are two distinct forms of cancer immunotherapy. Lifileucel is a tumour-infiltrating lymphocyte (TIL) therapy, which harnesses the power of a patient's immune system by extracting immune cells from a patient's tumour, multiplying them in a laboratory, and returning them to the bloodstream, allowing them to more effectively recognise and attack cancer cells.
Pembrolizumab is an immune checkpoint inhibitor, a type of drug that blocks proteins which normally restrain the immune system, allowing a patient's T cells to better detect and attack cancer cells.
Pembrolizumab is a proven first-line treatment for many patients with advanced melanoma. However, a significant fraction of patients do not experience long-lasting benefit. Lifileucel has been shown to offer a second chance at long-lasting cancer control when standard immunotherapies, including pembrolizumab, are no longer effective. The IOV-COM-202 trial sought to determine the potential benefit of combining both therapies as a first-line treatment.
Most trial participants experienced significant tumour shrinkage
The trial selected 27 patients with advanced melanoma and treated them with a combination of pembrolizumab and lifileucel. Patients first received chemotherapy to prepare the body for treatment, before receiving the cell infusion and a short course of interleukin-2, a drug that boosts immune cell activity and is given after TIL therapy to help the infused cells grow and attack the cancer.
Of the 27 patients treated, 24 were included in the trial's main analysis.
After a median follow-up period of 26.9 months, researchers found that 15 of the 24 patients (62.5 per cent) experienced significant tumour shrinkage, with approximately one third (29.2 per cent) of patients seeing their tumours disappear completely on scans.
The median duration of response had not yet been reached more than two years after the trial began, meaning that many patients who responded to treatment were still benefiting from it at the time of analysis.
Among the 15 patients whose cancer responded to treatment, 13 maintained their response for at least 12 months, while 10 remained in complete or partial response at their most recent assessment.
No additional side effects with combined approach
Median progression-free survival, which is the length of time before a patient's cancer returned or progressed, was 19.8 months. Median overall survival, the length of time within the trial that a patient remained alive, had not yet been reached after 50.9 months of follow-up.
Patients experienced no additional side effects beyond those associated with the individual treatments.
Researchers are now evaluating this approach in TILVANCE-301, an international Phase III trial comparing lifileucel plus pembrolizumab with pembrolizumab alone in patients with advanced melanoma, for which Dr Andrew Furness is the UK National Chief Investigator.
"Immune checkpoint inhibitors like pembrolizumab have transformed outcomes for patients with advanced melanoma, with around half of patients achieving long-term cancer control. However, for those that do not derive long-term benefit, novel therapeutic options are urgently required," explains Dr Andrew Furness.
"Our findings suggest that adding TIL therapy to first-line pembrolizumab can produce deep and durable responses. Larger studies will now help us understand which patients are most likely to benefit from this combination and how it can best be used alongside existing immunotherapies."
"My tumours disappeared after TIL therapy and pembrolizumab"
After being diagnosed with melanoma in 2024, Paul Jenner, 59, a former ballet dancer and landscape construction company owner from London, was referred to The Royal Marsden after tests showed his cancer had spread beyond the original site to nearby lymph nodes.
Paul joined the IOV-COM-202 trial and received TIL therapy and pembrolizumab in August 2024. His cancer is currently in remission.
"It's amazing, really, that your own cells can be used in this way and used to heal you," said Paul.
"Before I had the treatment, there was spread to my lung, there was a growth on my back and there were a couple of other areas doctors were keeping an eye on. These all disappeared after the TIL therapy and pembrolizumab.
"The Royal Marsden is an incredible place and there are such lovely people working there, from everyone on the wards to the research staff who talked me through the trial. You can't help but feel grateful to have the chance to have something like TIL therapy. I don't know where I'd be without it."
The IOV-COM-202 study is funded by Iovance Biotherapeutics, Inc. Solid tumour cellular therapy research at The Royal Marsden is funded by supporters of The Royal Marsden Cancer Charity including our charity partner Nationwide, and The National Institute for Health and Care Research (NIHR) Biomedical Research Centre at The Royal Marsden and the ICR.
Dr Andrew Furness' role is part-funded by The Royal Marsden Cancer Charity.
* * *
Original text here: https://www.royalmarsden.nhs.uk/news-and-events/news/nearly-one-third-patients-advanced-melanoma-saw-tumours-disappear-completely
International Myeloma Foundation Launches US Myeloma Network to Accelerate Clinical Trials, Expand Access, and Improve Patient Care
NORTH HOLLYWOOD, California, Oct. 24 -- The International Myeloma Foundation issued the following news:
* * *
The International Myeloma Foundation Launches US Myeloma Network to Accelerate Clinical Trials, Expand Access, and Improve Patient Care
STUDIO CITY, CA, October 22, 2026 -- Today, the International Myeloma Foundation (IMF) announced the launch of the US Myeloma Network (USMN) -- a first-of-its-kind national clinical research network designed to accelerate the prevention and cure of multiple myeloma by advancing scientific discovery, expanding access to clinical trials, and ensuring ... Show Full Article NORTH HOLLYWOOD, California, Oct. 24 -- The International Myeloma Foundation issued the following news: * * * The International Myeloma Foundation Launches US Myeloma Network to Accelerate Clinical Trials, Expand Access, and Improve Patient Care STUDIO CITY, CA, October 22, 2026 -- Today, the International Myeloma Foundation (IMF) announced the launch of the US Myeloma Network (USMN) -- a first-of-its-kind national clinical research network designed to accelerate the prevention and cure of multiple myeloma by advancing scientific discovery, expanding access to clinical trials, and ensuringmore patients benefit from breakthrough therapies. Johnson & Johnson joins this initiative as the network's first industry collaborator. The USMN will focus on clinical trials with the potential to change clinical practice across care settings, accelerating the delivery of innovative therapies and new treatment approaches to patients.
The USMN connects leading academic centers, community oncology practices and industry partners through a coordinated national infrastructure designed to streamline trial activation, reduce operational barriers, expand equitable access to clinical trials, and accelerate the development of more effective therapies across the continuum of myeloma care - from prevention and early intervention through relapsed and refractory disease.
"The future of myeloma depends on our ability to bring scientific innovation to patients more quickly and more equitably," said S. Vincent Rajkumar, MD, Mayo Clinic, Chairperson of the International Myeloma Foundation. "The US Myeloma Network creates an unprecedented opportunity to unite investigators across the country through a coordinated research infrastructure that accelerates clinical trials, expands patient participation, and advances the discoveries that will ultimately lead to the prevention--and one day the cure--of multiple myeloma."
Expanding equity in clinical research is a foundational principle of the USMN. Beyond increasing the availability of clinical trials, the network is committed to ensuring patients understand - and can confidently participate in - research through culturally responsive, linguistically appropriate education and community engagement designed in partnership with populations that have historically faced barriers to trial participation.
"Every breakthrough in myeloma begins with a patient who participates in research," said Heather Cooper Ortner, IMF President and CEO. "The US Myeloma Network is designed to ensure that more patients have that opportunity regardless of where they live. By making clinical research more accessible, more collaborative, and more inclusive, we will accelerate scientific discovery, bring promising therapies to patients faster, and move closer to preventing and curing this disease."
"Johnson & Johnson is proud to support the International Myeloma Foundation's US Myeloma Network as its first industry collaborator," said Imran Khan, M.D., Ph.D., Vice President, U.S. Hematology Medical Affairs, Johnson & Johnson. "At Johnson & Johnson, our ambition is to move closer to a future where multiple myeloma can be cured. Collaborations like this help advance the research and insights needed to accelerate progress toward that goal and improve outcomes for patients with multiple myeloma."
A cornerstone of the US Myeloma Network is its strategic collaboration with Sarah Cannon Development Innovations, LLC, which is Sarah Cannon Research Institute's (SCRI) CRO. Combining the IMF's internationally recognized scientific leadership, patient trust, and global research collaborations with Sarah Cannon Development Innovations' expertise in complex oncology trials establishes a powerful national research infrastructure capable of launching innovative studies faster, expanding equitable access to clinical trials, and accelerating progress for myeloma patients.
"The US Myeloma Network and SCRI share a common goal: expand access to innovative clinical research and bring promising therapies to patients faster," said Marcy Vallone, Senior Vice President of Sarah Cannon Development Innovations. "As an oncology-dedicated CRO, we are honored to support this important initiative by providing the infrastructure and operational expertise needed to deliver clinical trials across participating USMN sites. Together, we are creating more opportunities for patients, helping advance the next generation of therapies for multiple myeloma."
Through collaborating with biopharmaceutical companies, leading research centers, and community oncology practices, the USMN creates a more efficient pathway from scientific discovery to clinical practice - helping innovative therapies reach patients sooner.
US Myeloma Network: Building on the legacy of the IMF's mission
For nearly four decades, the IMF has united researchers, healthcare professionals, industry leaders, patients, and care partners around one shared mission: accelerating the prevention and cure of myeloma and improving the quality of life for patients and families.
The US Myeloma Network builds on that legacy by transforming how clinical research is conducted, expanding equitable access to innovation, and bringing the promise of scientific discovery to more patients than ever before.
Learn more about the US Myeloma Network (https://www.myeloma.org/usmn).
* * *
ABOUT MULTIPLE MYELOMA
Multiple myeloma is a cancer of the bone marrow plasma cells, white blood cells that make antibodies. A cancerous or malignant plasma cell is called a myeloma cell. Myeloma is called "multiple" because there are frequently multiple patches or areas in bone where it grows. It often causes damage to bones and kidneys. Multiple myeloma is still incurable, but great progress has been made in terms of survival over the last two decades. The disease is twice as common and is diagnosed at a younger age in Black and African Americans than White Americans. The most common symptoms include fatigue and bone pain.
* * *
ABOUT THE INTERNATIONAL MYELOMA FOUNDATION
Founded in 1990, the International Myeloma Foundation (IMF) is the world's leading organization dedicated to multiple myeloma. The IMF is steadfast in its mission: accelerating the prevention and cure of myeloma and improving the quality of life for patients and families. Through initiatives such as the US Myeloma Network, the International Myeloma Working Group, the Black Swan Research Initiative(R) (BSRI), and its comprehensive education, support, and advocacy programs, the IMF works to accelerate the prevention and cure of myeloma while ensuring every patient has equitable access to the latest scientific advances.
The IMF serves people impacted by myeloma at every stage of the disease by combining world-class research, trusted education, global advocacy, and direct support. A cornerstone of this work is the International Myeloma Working Group(R) (IMWG), a network of more than 380 internationally renowned researchers and clinicians who establish guidelines that shape how myeloma is diagnosed, treated, and managed across the globe.
Through its global network of support groups, educational programs, its 24/7 generative-AI myeloma assistant Myelo(R), its InfoLine, and its advocacy for greater healthcare access, the IMF helps people living with myeloma and their care partners navigate diagnosis, treatment, and survivorship. At the same time, the IMF ensures scientific advances translate into better care and outcomes.
Learn more at www.myeloma.org or contact the IMF InfoLine at (800) 452-CURE (2873) (U.S. & Canada), +1 (818) 487-7455 (worldwide), or infoline@myeloma.org.
* * *
Original text here: https://www.myeloma.org/news-events/multiple-myeloma-news/international-myeloma-foundation-launches-us-myeloma-network-accelerate-clinical-trials-expand
* * *
The International Myeloma Foundation Launches US Myeloma Network to Accelerate Clinical Trials, Expand Access, and Improve Patient Care
STUDIO CITY, CA, October 22, 2026 -- Today, the International Myeloma Foundation (IMF) announced the launch of the US Myeloma Network (USMN) -- a first-of-its-kind national clinical research network designed to accelerate the prevention and cure of multiple myeloma by advancing scientific discovery, expanding access to clinical trials, and ensuring ... Show Full Article NORTH HOLLYWOOD, California, Oct. 24 -- The International Myeloma Foundation issued the following news: * * * The International Myeloma Foundation Launches US Myeloma Network to Accelerate Clinical Trials, Expand Access, and Improve Patient Care STUDIO CITY, CA, October 22, 2026 -- Today, the International Myeloma Foundation (IMF) announced the launch of the US Myeloma Network (USMN) -- a first-of-its-kind national clinical research network designed to accelerate the prevention and cure of multiple myeloma by advancing scientific discovery, expanding access to clinical trials, and ensuringmore patients benefit from breakthrough therapies. Johnson & Johnson joins this initiative as the network's first industry collaborator. The USMN will focus on clinical trials with the potential to change clinical practice across care settings, accelerating the delivery of innovative therapies and new treatment approaches to patients.
The USMN connects leading academic centers, community oncology practices and industry partners through a coordinated national infrastructure designed to streamline trial activation, reduce operational barriers, expand equitable access to clinical trials, and accelerate the development of more effective therapies across the continuum of myeloma care - from prevention and early intervention through relapsed and refractory disease.
"The future of myeloma depends on our ability to bring scientific innovation to patients more quickly and more equitably," said S. Vincent Rajkumar, MD, Mayo Clinic, Chairperson of the International Myeloma Foundation. "The US Myeloma Network creates an unprecedented opportunity to unite investigators across the country through a coordinated research infrastructure that accelerates clinical trials, expands patient participation, and advances the discoveries that will ultimately lead to the prevention--and one day the cure--of multiple myeloma."
Expanding equity in clinical research is a foundational principle of the USMN. Beyond increasing the availability of clinical trials, the network is committed to ensuring patients understand - and can confidently participate in - research through culturally responsive, linguistically appropriate education and community engagement designed in partnership with populations that have historically faced barriers to trial participation.
"Every breakthrough in myeloma begins with a patient who participates in research," said Heather Cooper Ortner, IMF President and CEO. "The US Myeloma Network is designed to ensure that more patients have that opportunity regardless of where they live. By making clinical research more accessible, more collaborative, and more inclusive, we will accelerate scientific discovery, bring promising therapies to patients faster, and move closer to preventing and curing this disease."
"Johnson & Johnson is proud to support the International Myeloma Foundation's US Myeloma Network as its first industry collaborator," said Imran Khan, M.D., Ph.D., Vice President, U.S. Hematology Medical Affairs, Johnson & Johnson. "At Johnson & Johnson, our ambition is to move closer to a future where multiple myeloma can be cured. Collaborations like this help advance the research and insights needed to accelerate progress toward that goal and improve outcomes for patients with multiple myeloma."
A cornerstone of the US Myeloma Network is its strategic collaboration with Sarah Cannon Development Innovations, LLC, which is Sarah Cannon Research Institute's (SCRI) CRO. Combining the IMF's internationally recognized scientific leadership, patient trust, and global research collaborations with Sarah Cannon Development Innovations' expertise in complex oncology trials establishes a powerful national research infrastructure capable of launching innovative studies faster, expanding equitable access to clinical trials, and accelerating progress for myeloma patients.
"The US Myeloma Network and SCRI share a common goal: expand access to innovative clinical research and bring promising therapies to patients faster," said Marcy Vallone, Senior Vice President of Sarah Cannon Development Innovations. "As an oncology-dedicated CRO, we are honored to support this important initiative by providing the infrastructure and operational expertise needed to deliver clinical trials across participating USMN sites. Together, we are creating more opportunities for patients, helping advance the next generation of therapies for multiple myeloma."
Through collaborating with biopharmaceutical companies, leading research centers, and community oncology practices, the USMN creates a more efficient pathway from scientific discovery to clinical practice - helping innovative therapies reach patients sooner.
US Myeloma Network: Building on the legacy of the IMF's mission
For nearly four decades, the IMF has united researchers, healthcare professionals, industry leaders, patients, and care partners around one shared mission: accelerating the prevention and cure of myeloma and improving the quality of life for patients and families.
The US Myeloma Network builds on that legacy by transforming how clinical research is conducted, expanding equitable access to innovation, and bringing the promise of scientific discovery to more patients than ever before.
Learn more about the US Myeloma Network (https://www.myeloma.org/usmn).
* * *
ABOUT MULTIPLE MYELOMA
Multiple myeloma is a cancer of the bone marrow plasma cells, white blood cells that make antibodies. A cancerous or malignant plasma cell is called a myeloma cell. Myeloma is called "multiple" because there are frequently multiple patches or areas in bone where it grows. It often causes damage to bones and kidneys. Multiple myeloma is still incurable, but great progress has been made in terms of survival over the last two decades. The disease is twice as common and is diagnosed at a younger age in Black and African Americans than White Americans. The most common symptoms include fatigue and bone pain.
* * *
ABOUT THE INTERNATIONAL MYELOMA FOUNDATION
Founded in 1990, the International Myeloma Foundation (IMF) is the world's leading organization dedicated to multiple myeloma. The IMF is steadfast in its mission: accelerating the prevention and cure of myeloma and improving the quality of life for patients and families. Through initiatives such as the US Myeloma Network, the International Myeloma Working Group, the Black Swan Research Initiative(R) (BSRI), and its comprehensive education, support, and advocacy programs, the IMF works to accelerate the prevention and cure of myeloma while ensuring every patient has equitable access to the latest scientific advances.
The IMF serves people impacted by myeloma at every stage of the disease by combining world-class research, trusted education, global advocacy, and direct support. A cornerstone of this work is the International Myeloma Working Group(R) (IMWG), a network of more than 380 internationally renowned researchers and clinicians who establish guidelines that shape how myeloma is diagnosed, treated, and managed across the globe.
Through its global network of support groups, educational programs, its 24/7 generative-AI myeloma assistant Myelo(R), its InfoLine, and its advocacy for greater healthcare access, the IMF helps people living with myeloma and their care partners navigate diagnosis, treatment, and survivorship. At the same time, the IMF ensures scientific advances translate into better care and outcomes.
Learn more at www.myeloma.org or contact the IMF InfoLine at (800) 452-CURE (2873) (U.S. & Canada), +1 (818) 487-7455 (worldwide), or infoline@myeloma.org.
* * *
Original text here: https://www.myeloma.org/news-events/multiple-myeloma-news/international-myeloma-foundation-launches-us-myeloma-network-accelerate-clinical-trials-expand
Freedom From Religion Foundation: 'Secular Spotlight' Welcomes Back Taylor 'The Antibot' Leigh for Satanism Discussion
MADISON, Wisconsin, Oct. 24 -- The Freedom From Religion Foundation issued the following news release:
* * *
October 23, 2026
'Secular Spotlight' welcomes back Taylor 'The Antibot' Leigh for satanism discussion
The latest episode of FFRF's YouTube series "Secular Spotlight" welcomes back Taylor "The Antibot" Leigh to discuss her nontheistic satanic lifestyle.
Leigh explains what led her to nontheistic satanism and the value of secular rituals. Drawing on her journey out of evangelical Christianity, Leigh discusses healing from religious trauma, finding community, reclaiming once-feared symbols ... Show Full Article MADISON, Wisconsin, Oct. 24 -- The Freedom From Religion Foundation issued the following news release: * * * October 23, 2026 'Secular Spotlight' welcomes back Taylor 'The Antibot' Leigh for satanism discussion The latest episode of FFRF's YouTube series "Secular Spotlight" welcomes back Taylor "The Antibot" Leigh to discuss her nontheistic satanic lifestyle. Leigh explains what led her to nontheistic satanism and the value of secular rituals. Drawing on her journey out of evangelical Christianity, Leigh discusses healing from religious trauma, finding community, reclaiming once-feared symbols-- and learning to live authentically beyond the expectations of religion.
"A big misconception about Satanism, and this is primarily among Christians ... is that Satanism inherently has to do with worshiping or believing in the devil, which most satanists do not believe exists," Leigh explains. "Satan, for me, symbolizes freedom, intellectualism [and] living authentically."
You can catch this episode of "Secular Spotlight" on FFRF's YouTube channel, or on your smart TV after downloading FFRF's free app, Freethought TV, which also highlights FFRF's other video programming. Previous episodes explore online comedian Kevin Crowe's satirical approach to calling out religious bigotry, as well as a deep dive into still-existing blasphemy laws in America. Make sure you're subscribed to FFRF's YouTube channel for all the latest updates!
* * *
The Freedom From Religion Foundation is a U.S.-based nonprofit dedicated to defending the constitutional principle of separation between state and church and educating the public on matters relating to nontheism. With more than 40,000 members across the country, FFRF is the largest association of freethinkers (atheists, agnostics and humanists) in North America. For more information, visit ffrf.org.
* * *
Original text here: https://ffrf.org/news/releases/secular-spotlight-welcomes-back-taylor-the-antibot-leigh-for-satanism-discussion/
[Category: Religion]
* * *
October 23, 2026
'Secular Spotlight' welcomes back Taylor 'The Antibot' Leigh for satanism discussion
The latest episode of FFRF's YouTube series "Secular Spotlight" welcomes back Taylor "The Antibot" Leigh to discuss her nontheistic satanic lifestyle.
Leigh explains what led her to nontheistic satanism and the value of secular rituals. Drawing on her journey out of evangelical Christianity, Leigh discusses healing from religious trauma, finding community, reclaiming once-feared symbols ... Show Full Article MADISON, Wisconsin, Oct. 24 -- The Freedom From Religion Foundation issued the following news release: * * * October 23, 2026 'Secular Spotlight' welcomes back Taylor 'The Antibot' Leigh for satanism discussion The latest episode of FFRF's YouTube series "Secular Spotlight" welcomes back Taylor "The Antibot" Leigh to discuss her nontheistic satanic lifestyle. Leigh explains what led her to nontheistic satanism and the value of secular rituals. Drawing on her journey out of evangelical Christianity, Leigh discusses healing from religious trauma, finding community, reclaiming once-feared symbols-- and learning to live authentically beyond the expectations of religion.
"A big misconception about Satanism, and this is primarily among Christians ... is that Satanism inherently has to do with worshiping or believing in the devil, which most satanists do not believe exists," Leigh explains. "Satan, for me, symbolizes freedom, intellectualism [and] living authentically."
You can catch this episode of "Secular Spotlight" on FFRF's YouTube channel, or on your smart TV after downloading FFRF's free app, Freethought TV, which also highlights FFRF's other video programming. Previous episodes explore online comedian Kevin Crowe's satirical approach to calling out religious bigotry, as well as a deep dive into still-existing blasphemy laws in America. Make sure you're subscribed to FFRF's YouTube channel for all the latest updates!
* * *
The Freedom From Religion Foundation is a U.S.-based nonprofit dedicated to defending the constitutional principle of separation between state and church and educating the public on matters relating to nontheism. With more than 40,000 members across the country, FFRF is the largest association of freethinkers (atheists, agnostics and humanists) in North America. For more information, visit ffrf.org.
* * *
Original text here: https://ffrf.org/news/releases/secular-spotlight-welcomes-back-taylor-the-antibot-leigh-for-satanism-discussion/
[Category: Religion]
FGA Applauds USDA Proposal to Protect Food Stamps From Skimmers and Thieves
NAPLES, Florida, Oct. 24 -- The Foundation for Government Accountability posted the following news release:
* * *
FGA Applauds USDA Proposal to Protect Food Stamps From Skimmers and Thieves
October 22, 2026
New Trump administration rule would require chip-enabled food stamp cards to stop the skimming rings that have stolen hundreds of millions of dollars from low-income families.
-
WASHINGTON, D.C. -- Today, the Foundation for Government Accountability (FGA) issued the following statement in strong support of the U.S. Department of Agriculture's (USDA) proposed rule that requires food stamp ... Show Full Article NAPLES, Florida, Oct. 24 -- The Foundation for Government Accountability posted the following news release: * * * FGA Applauds USDA Proposal to Protect Food Stamps From Skimmers and Thieves October 22, 2026 New Trump administration rule would require chip-enabled food stamp cards to stop the skimming rings that have stolen hundreds of millions of dollars from low-income families. - WASHINGTON, D.C. -- Today, the Foundation for Government Accountability (FGA) issued the following statement in strong support of the U.S. Department of Agriculture's (USDA) proposed rule that requires food stampcards to be chip and tap-enabled with enhanced security features; gives households the ability to monitor their accounts, block out-of-state transactions, and protect their cards; and requires states to improve monitoring of EBT terminals.
"Under the leadership of President Trump and Vice President Vance, the War on Fraud has gone after those who wrongly seek to profit off Americans' generosity--this rule takes the war to the checkout line," said Jonathan Ingram, Vice President of Policy and Research at FGA. "This week alone, the Justice Department and USDA took action against more than 40 defendants in schemes targeting tens of millions in food stamp benefits, including foreign crime rings that skimmed card numbers and drained families' accounts."
"With a move to chip technology, which is already the standard for debit and credit cards, outdated cards will no longer be an easy payday for fraudsters and money meant for the truly needy will stay where it belongs," continued Ingram. "This is commonsense program integrity that will protect low-income families across the country."
Additional Information
Most food stamp cards still run on magnetic-stripe technology that banks moved away from years ago, and it has left them vulnerable to fraud. Skimming rings hide devices on store card readers and copy the card numbers. They then use these numbers to build counterfeit cards and drain benefits meant for groceries. Between October 2022 and December 2024, the federal government replaced more than $360 million in stolen food stamp benefits for more than 750,000 households. USDA's inspector general projected that another $233 million could be lost over the following two years.
This week, the Justice Department and USDA announced enforcement actions against more than 40 defendants in cases involving nearly $42 million in food stamp fraud. In the largest, two Chicago store owners allegedly ran stolen Ohio EBT cards through their registers, sometimes only seconds apart, in a scheme worth nearly $30 million. The Biden administration approved both stores to accept food stamps. Prosecutors say some of the money bought cars that were shipped overseas. In another case, a crew made up mostly of Romanian nationals in the country illegally used skimming devices to steal benefits, and its partners shipped more than 124,000 pounds of baby formula bought with those benefits for resale on the black market.
For more on welfare program integrity, visit https://thefga.org/solution/promoting-work-over-welfare/.
* * *
The Foundation for Government Accountability (FGA) is a non-profit think tank that promotes public policy solutions in all 50 states to create opportunities for every American to experience the American Dream. To learn more, visit TheFGA.org.
* * *
Original text here: https://thefga.org/press/fga-applauds-usda-proposal-to-protect-food-stamps-from-skimmers-and-thieves/
* * *
FGA Applauds USDA Proposal to Protect Food Stamps From Skimmers and Thieves
October 22, 2026
New Trump administration rule would require chip-enabled food stamp cards to stop the skimming rings that have stolen hundreds of millions of dollars from low-income families.
-
WASHINGTON, D.C. -- Today, the Foundation for Government Accountability (FGA) issued the following statement in strong support of the U.S. Department of Agriculture's (USDA) proposed rule that requires food stamp ... Show Full Article NAPLES, Florida, Oct. 24 -- The Foundation for Government Accountability posted the following news release: * * * FGA Applauds USDA Proposal to Protect Food Stamps From Skimmers and Thieves October 22, 2026 New Trump administration rule would require chip-enabled food stamp cards to stop the skimming rings that have stolen hundreds of millions of dollars from low-income families. - WASHINGTON, D.C. -- Today, the Foundation for Government Accountability (FGA) issued the following statement in strong support of the U.S. Department of Agriculture's (USDA) proposed rule that requires food stampcards to be chip and tap-enabled with enhanced security features; gives households the ability to monitor their accounts, block out-of-state transactions, and protect their cards; and requires states to improve monitoring of EBT terminals.
"Under the leadership of President Trump and Vice President Vance, the War on Fraud has gone after those who wrongly seek to profit off Americans' generosity--this rule takes the war to the checkout line," said Jonathan Ingram, Vice President of Policy and Research at FGA. "This week alone, the Justice Department and USDA took action against more than 40 defendants in schemes targeting tens of millions in food stamp benefits, including foreign crime rings that skimmed card numbers and drained families' accounts."
"With a move to chip technology, which is already the standard for debit and credit cards, outdated cards will no longer be an easy payday for fraudsters and money meant for the truly needy will stay where it belongs," continued Ingram. "This is commonsense program integrity that will protect low-income families across the country."
Additional Information
Most food stamp cards still run on magnetic-stripe technology that banks moved away from years ago, and it has left them vulnerable to fraud. Skimming rings hide devices on store card readers and copy the card numbers. They then use these numbers to build counterfeit cards and drain benefits meant for groceries. Between October 2022 and December 2024, the federal government replaced more than $360 million in stolen food stamp benefits for more than 750,000 households. USDA's inspector general projected that another $233 million could be lost over the following two years.
This week, the Justice Department and USDA announced enforcement actions against more than 40 defendants in cases involving nearly $42 million in food stamp fraud. In the largest, two Chicago store owners allegedly ran stolen Ohio EBT cards through their registers, sometimes only seconds apart, in a scheme worth nearly $30 million. The Biden administration approved both stores to accept food stamps. Prosecutors say some of the money bought cars that were shipped overseas. In another case, a crew made up mostly of Romanian nationals in the country illegally used skimming devices to steal benefits, and its partners shipped more than 124,000 pounds of baby formula bought with those benefits for resale on the black market.
For more on welfare program integrity, visit https://thefga.org/solution/promoting-work-over-welfare/.
* * *
The Foundation for Government Accountability (FGA) is a non-profit think tank that promotes public policy solutions in all 50 states to create opportunities for every American to experience the American Dream. To learn more, visit TheFGA.org.
* * *
Original text here: https://thefga.org/press/fga-applauds-usda-proposal-to-protect-food-stamps-from-skimmers-and-thieves/
Effigy Mounds Visitor Center to Undergo Renovations Made Possible by $3.5 Million in Philanthropic Support Through the National Park Foundation
NEW YORK, Oct. 24 -- The Leona M. and Harry B. Helmsley Charitable Trust posted the following news release:
* * *
Effigy Mounds Visitor Center to Undergo Renovations Made Possible by $3.5 Million in Philanthropic Support Through the National Park Foundation
*
The National Park Foundation (NPF), the nation's most trusted way for people to support America's national parks, today announced $3.5 million in philanthropic support for new exhibits and an educational film at the revitalized visitor center at Effigy Mounds National Monument in Harper Ferry, Iowa. The funding was made possible with a ... Show Full Article NEW YORK, Oct. 24 -- The Leona M. and Harry B. Helmsley Charitable Trust posted the following news release: * * * Effigy Mounds Visitor Center to Undergo Renovations Made Possible by $3.5 Million in Philanthropic Support Through the National Park Foundation * The National Park Foundation (NPF), the nation's most trusted way for people to support America's national parks, today announced $3.5 million in philanthropic support for new exhibits and an educational film at the revitalized visitor center at Effigy Mounds National Monument in Harper Ferry, Iowa. The funding was made possible with a$3 million grant from The Leona M. and Harry B. Helmsley Charitable Trust and a $500,000 grant from Lilly Endowment Inc.
This funding will help the renovated visitor center tell the full story of this historical park site. Through the exhibits and film, the National Park Service (NPS), the local community, and the 19 tribal nations that are affiliated with the monument will work together on a truthful account of the site's cultural heritage, alongside its spiritual, geological, archaeological, and historic significance.
"The renovated visitor center at Effigy Mounds will give people a welcoming, accessible place to begin their visit and understand what makes this landscape so extraordinary," said Mike Reynolds, Chief Program Officer at the National Park Foundation. "Thanks to the generosity of Helmsley Charitable Trust and Lilly Endowment, new exhibits and a new park film will share the story of this park, told through the voices of affiliated tribal nations, with every visitor who comes through the doors."
The center will invite first-time and returning visitors to stay longer and offer meaningful learning experiences to those who cannot use the park's trails. A new 20-minute film, produced in high definition with open captions and audio description, will feature the voices of tribal representatives and support ongoing work to build relationships and further healing with tribal nations whose history and perspectives have too often been misrepresented or left out.
Together, the exhibits and film will help visitors understand the deep connections between the mounds, the surrounding landscape, and the tribal nations for whom these places are culturally and spiritually significant, linking the stories shared inside the visitor center to the resources beyond its doors.
"Effigy Mounds is a place of profound cultural, historical, and spiritual significance, and its story deserves to be told with the depth, honesty, and respect it deserves," said Walter Panzirer, a Trustee of the Helmsley Charitable Trust. "We are proud to support a visitor experience that honors the tribal nations connected to this sacred landscape and gives more people the opportunity to learn, reflect, and connect with nature. We know that access to the outdoors is important to health and well-being, and we hope this renewed visitor center will help visitors build a deeper connection to this extraordinary place."
Effigy Mounds National Monument preserves outstanding examples of mounds built by Indigenous peoples of the American Midwest. The area's natural resources and beauty lay beyond the reach of the last glacial advance, which made it an ideal place to gather, celebrate, and build mounds together. These earthworks were a regional cultural phenomenon with many shaped like birds, bears, deer, bison, lynx, turtles, and water spirits.
For the 19 tribal nations affiliated with the monument, the mounds are more than sites for archaeological and scientific study: they are places of interconnected cultural and spiritual significance. Lilly Endowment's grant was approved through its Religion and Cultural Institutions Initiative.
"We appreciate the National Park Foundation and the generous support provided by the Helmsley Charitable Trust and Lilly Endowment Inc. for this important project," said Susan Snow, superintendent of Effigy Mounds National Monument. "These new exhibits and educational materials will help us share the monument's rich history and cultural significance, working with our affiliated tribal nations to enhance the visitor experience."
The Great American Outdoors Act Legacy Restoration Fund is funding the rehabilitation of the visitor center building, which will improve its layout, accessibility, and building systems, and address moisture problems affecting the museum collection and indoor air quality. Federal Highway Administration funds are also supporting a parking lot improvement project.
The new visitor center is expected to open in Summer 2029.
About the National Park Foundation
The National Park Foundation is the nation's most trusted way for people to support America's national parks. We work with the National Park Service and partners across the country to fund priority projects that keep parks strong, relevant, and accessible. This work helps ensure parks continue to inspire pride across the country and offer experiences that create meaningful connection. In 2025, NPF funded $100 million in on-the-ground priority projects nationwide, made possible through the generosity of donors, to advance critical work, including infrastructure, restoration, education, and access, ensuring parks continue to endure for generations to come. Learn more at nationalparks.org and follow NPF on Instagram, Facebook, X, LinkedIn, and TikTok.
***
Original text here: https://helmsleytrust.org/news-and-insights/effigy-mounds-visitor-center-to-undergo-renovations-made-possible-by-3-5-million-in-philanthropic-support-through-the-national-park-foundation/
* * *
Effigy Mounds Visitor Center to Undergo Renovations Made Possible by $3.5 Million in Philanthropic Support Through the National Park Foundation
*
The National Park Foundation (NPF), the nation's most trusted way for people to support America's national parks, today announced $3.5 million in philanthropic support for new exhibits and an educational film at the revitalized visitor center at Effigy Mounds National Monument in Harper Ferry, Iowa. The funding was made possible with a ... Show Full Article NEW YORK, Oct. 24 -- The Leona M. and Harry B. Helmsley Charitable Trust posted the following news release: * * * Effigy Mounds Visitor Center to Undergo Renovations Made Possible by $3.5 Million in Philanthropic Support Through the National Park Foundation * The National Park Foundation (NPF), the nation's most trusted way for people to support America's national parks, today announced $3.5 million in philanthropic support for new exhibits and an educational film at the revitalized visitor center at Effigy Mounds National Monument in Harper Ferry, Iowa. The funding was made possible with a$3 million grant from The Leona M. and Harry B. Helmsley Charitable Trust and a $500,000 grant from Lilly Endowment Inc.
This funding will help the renovated visitor center tell the full story of this historical park site. Through the exhibits and film, the National Park Service (NPS), the local community, and the 19 tribal nations that are affiliated with the monument will work together on a truthful account of the site's cultural heritage, alongside its spiritual, geological, archaeological, and historic significance.
"The renovated visitor center at Effigy Mounds will give people a welcoming, accessible place to begin their visit and understand what makes this landscape so extraordinary," said Mike Reynolds, Chief Program Officer at the National Park Foundation. "Thanks to the generosity of Helmsley Charitable Trust and Lilly Endowment, new exhibits and a new park film will share the story of this park, told through the voices of affiliated tribal nations, with every visitor who comes through the doors."
The center will invite first-time and returning visitors to stay longer and offer meaningful learning experiences to those who cannot use the park's trails. A new 20-minute film, produced in high definition with open captions and audio description, will feature the voices of tribal representatives and support ongoing work to build relationships and further healing with tribal nations whose history and perspectives have too often been misrepresented or left out.
Together, the exhibits and film will help visitors understand the deep connections between the mounds, the surrounding landscape, and the tribal nations for whom these places are culturally and spiritually significant, linking the stories shared inside the visitor center to the resources beyond its doors.
"Effigy Mounds is a place of profound cultural, historical, and spiritual significance, and its story deserves to be told with the depth, honesty, and respect it deserves," said Walter Panzirer, a Trustee of the Helmsley Charitable Trust. "We are proud to support a visitor experience that honors the tribal nations connected to this sacred landscape and gives more people the opportunity to learn, reflect, and connect with nature. We know that access to the outdoors is important to health and well-being, and we hope this renewed visitor center will help visitors build a deeper connection to this extraordinary place."
Effigy Mounds National Monument preserves outstanding examples of mounds built by Indigenous peoples of the American Midwest. The area's natural resources and beauty lay beyond the reach of the last glacial advance, which made it an ideal place to gather, celebrate, and build mounds together. These earthworks were a regional cultural phenomenon with many shaped like birds, bears, deer, bison, lynx, turtles, and water spirits.
For the 19 tribal nations affiliated with the monument, the mounds are more than sites for archaeological and scientific study: they are places of interconnected cultural and spiritual significance. Lilly Endowment's grant was approved through its Religion and Cultural Institutions Initiative.
"We appreciate the National Park Foundation and the generous support provided by the Helmsley Charitable Trust and Lilly Endowment Inc. for this important project," said Susan Snow, superintendent of Effigy Mounds National Monument. "These new exhibits and educational materials will help us share the monument's rich history and cultural significance, working with our affiliated tribal nations to enhance the visitor experience."
The Great American Outdoors Act Legacy Restoration Fund is funding the rehabilitation of the visitor center building, which will improve its layout, accessibility, and building systems, and address moisture problems affecting the museum collection and indoor air quality. Federal Highway Administration funds are also supporting a parking lot improvement project.
The new visitor center is expected to open in Summer 2029.
About the National Park Foundation
The National Park Foundation is the nation's most trusted way for people to support America's national parks. We work with the National Park Service and partners across the country to fund priority projects that keep parks strong, relevant, and accessible. This work helps ensure parks continue to inspire pride across the country and offer experiences that create meaningful connection. In 2025, NPF funded $100 million in on-the-ground priority projects nationwide, made possible through the generosity of donors, to advance critical work, including infrastructure, restoration, education, and access, ensuring parks continue to endure for generations to come. Learn more at nationalparks.org and follow NPF on Instagram, Facebook, X, LinkedIn, and TikTok.
***
Original text here: https://helmsleytrust.org/news-and-insights/effigy-mounds-visitor-center-to-undergo-renovations-made-possible-by-3-5-million-in-philanthropic-support-through-the-national-park-foundation/
Anker Eufy Earns Asthma & Allergy Friendly Certification for Robot Vacuum Omni E35
ARLINGTON, Virginia, Oct. 24 -- The Asthma and Allergy Foundation of America issued the following news release:
* * *
Anker eufy Earns Asthma & Allergy Friendly(R) Certification for Robot Vacuum Omni E35
Certified Anker eufy Robot Vacuum Omni E35 supports healthier homes through proven allergen reduction and consistent cleaning performance
-
Washington, D.C., October 22, 2026 - The Asthma and Allergy Foundation of America (AAFA) and Allergy Standards Limited (ASL) announce that the Anker eufy Robot Vacuum Omni E35 earned the Asthma & Allergy Friendly(R) Certification.
The Asthma & Allergy ... Show Full Article ARLINGTON, Virginia, Oct. 24 -- The Asthma and Allergy Foundation of America issued the following news release: * * * Anker eufy Earns Asthma & Allergy Friendly(R) Certification for Robot Vacuum Omni E35 Certified Anker eufy Robot Vacuum Omni E35 supports healthier homes through proven allergen reduction and consistent cleaning performance - Washington, D.C., October 22, 2026 - The Asthma and Allergy Foundation of America (AAFA) and Allergy Standards Limited (ASL) announce that the Anker eufy Robot Vacuum Omni E35 earned the Asthma & Allergy Friendly(R) Certification. The Asthma & AllergyFriendly Certification Program, a collaborative initiative between the Asthma and Allergy Foundation of America (AAFA) and Allergy Standards Limited (ASL), helps consumers identify products that contribute to a healthier indoor environment.
Regular vacuuming plays a key role in reducing indoor allergens, helping to remove dust, dirt, and allergens from carpets, rugs, and floors, preventing particles from becoming airborne - a meaningful contribution to addressing indoor air pollution, which the U.S. Environmental Protection Agency ranks among the top five environmental risks to public health.
For the more than 106 million Americans living with asthma and allergies, a vacuum cleaner that effectively captures and contains allergens, rather than redistributing them into the air, plays a key role in managing indoor triggers.
To earn the certification, the Anker eufy Robot Vacuum Omni E35 underwent rigorous scientific testing and met or exceeded the Program's standards, demonstrating its ability to:
* Remove allergens from floors: Remove at least 90% of tested allergens from hard floors and at least 80% from carpet. Allergens assessed under the standard include cat and dust mite allergens.
* Effectively remove household dust: Remove at least 75% of test dust from hard floors and at least 40% from carpet.
* Limit airborne particles and allergens during use: Keep fine airborne particles and cat allergen below strict certification limits while vacuuming.
* Maintain low particle emissions: Keep fine particle emissions low even when operating on a clean floor, demonstrating that the vacuum itself does not release excessive dust into the air.
* Maintain pick-up performance: Demonstrate no more than a 10% loss in pick-up efficiency after two passes.
* Limit exposure when emptying the dust bin: Keep fine particles and cat allergen below certification limits during dust-bin emptying.
The certification adds the Anker eufy Robot Vacuum Omni E35 to the Program's list of independently certified vacuum cleaners, giving households a further science-backed option for reducing allergen exposure during everyday cleaning.
"For most families, the dust that matters most is the dust you can't see: pet dander, dust mite allergens and fine particles that settle into carpets and onto floors. That's the problem we set out to solve with the Robot Vacuum Omni E35, picking up those allergens and keeping them contained rather than sending them back into the air. We're proud that the Omni E35 has earned the Asthma & Allergy Friendly(R) Certification. It's an independent, science-based standard that requires products to prove what they remove through rigorous testing, rather than simply claiming it, and for Anker eufy, that's exactly the bar we want to be measured against," said Frank Zhu, President of Smart Innovations, Anker Innovations.
"People spend 90% of their time indoors and managing exposure to indoor allergens and airway irritants is an important way to control allergy and asthma symptoms," said Kenneth Mendez, president and CEO of AAFA. "By meeting the strict standards of the Asthma & Allergy Friendly(R) Certification program, Anker's eufy Robot Vacuum Omni E35 provides homeowners with another tool that can be a part of effective indoor air quality management."
"As robotic vacuums become a standard part of home cleaning, it's important that consumers have independent, science-based proof that these devices actually reduce allergen exposure. The eufy Robot Vacuum Omni E35 met that standard by demonstrating effective allergen removal while keeping airborne particle levels low during vacuuming and dust-bin emptying, giving people with asthma and allergies clear evidence that this product supports a healthier home," said Dr John McKeon, CEO of Allergy Standards Ltd.
* * *
About the Asthma & Allergy Friendly(R) Certification Program
The Asthma & Allergy Friendly(R) Certification Program is a collaboration between the Asthma and Allergy Foundation of America (AAFA) and Allergy Standards Limited (ASL) that tests and certifies products against strict standards to prove their suitability for people with asthma and allergies. Certified products include air cleaners, air filters, paints, bedding, vacuum cleaners, washing machines, cleaning products, flooring, and more. More information is available at aafa.org/certified.
* * *
About Anker eufy
Anker eufy specializes in AI-driven smart living solutions. Since 2016, we have introduced a wide range of products, from home security systems, robot vacuums, and robot lawn mowers to baby care and personal health devices. Anker Innovations (SZSE: 300866; HKEX: 00668) is a consumer technology company founded in 2011, serving more than 200 million customers across over 180 countries and regions. More information is available at https://www.eufy.com/eufy-robot-vacuum-omni-e35
* * *
Original text here: https://aafa.org/anker-eufy-earns-asthma-allergy-friendly-certification-for-robot-vacuum-omni-e35/
* * *
Anker eufy Earns Asthma & Allergy Friendly(R) Certification for Robot Vacuum Omni E35
Certified Anker eufy Robot Vacuum Omni E35 supports healthier homes through proven allergen reduction and consistent cleaning performance
-
Washington, D.C., October 22, 2026 - The Asthma and Allergy Foundation of America (AAFA) and Allergy Standards Limited (ASL) announce that the Anker eufy Robot Vacuum Omni E35 earned the Asthma & Allergy Friendly(R) Certification.
The Asthma & Allergy ... Show Full Article ARLINGTON, Virginia, Oct. 24 -- The Asthma and Allergy Foundation of America issued the following news release: * * * Anker eufy Earns Asthma & Allergy Friendly(R) Certification for Robot Vacuum Omni E35 Certified Anker eufy Robot Vacuum Omni E35 supports healthier homes through proven allergen reduction and consistent cleaning performance - Washington, D.C., October 22, 2026 - The Asthma and Allergy Foundation of America (AAFA) and Allergy Standards Limited (ASL) announce that the Anker eufy Robot Vacuum Omni E35 earned the Asthma & Allergy Friendly(R) Certification. The Asthma & AllergyFriendly Certification Program, a collaborative initiative between the Asthma and Allergy Foundation of America (AAFA) and Allergy Standards Limited (ASL), helps consumers identify products that contribute to a healthier indoor environment.
Regular vacuuming plays a key role in reducing indoor allergens, helping to remove dust, dirt, and allergens from carpets, rugs, and floors, preventing particles from becoming airborne - a meaningful contribution to addressing indoor air pollution, which the U.S. Environmental Protection Agency ranks among the top five environmental risks to public health.
For the more than 106 million Americans living with asthma and allergies, a vacuum cleaner that effectively captures and contains allergens, rather than redistributing them into the air, plays a key role in managing indoor triggers.
To earn the certification, the Anker eufy Robot Vacuum Omni E35 underwent rigorous scientific testing and met or exceeded the Program's standards, demonstrating its ability to:
* Remove allergens from floors: Remove at least 90% of tested allergens from hard floors and at least 80% from carpet. Allergens assessed under the standard include cat and dust mite allergens.
* Effectively remove household dust: Remove at least 75% of test dust from hard floors and at least 40% from carpet.
* Limit airborne particles and allergens during use: Keep fine airborne particles and cat allergen below strict certification limits while vacuuming.
* Maintain low particle emissions: Keep fine particle emissions low even when operating on a clean floor, demonstrating that the vacuum itself does not release excessive dust into the air.
* Maintain pick-up performance: Demonstrate no more than a 10% loss in pick-up efficiency after two passes.
* Limit exposure when emptying the dust bin: Keep fine particles and cat allergen below certification limits during dust-bin emptying.
The certification adds the Anker eufy Robot Vacuum Omni E35 to the Program's list of independently certified vacuum cleaners, giving households a further science-backed option for reducing allergen exposure during everyday cleaning.
"For most families, the dust that matters most is the dust you can't see: pet dander, dust mite allergens and fine particles that settle into carpets and onto floors. That's the problem we set out to solve with the Robot Vacuum Omni E35, picking up those allergens and keeping them contained rather than sending them back into the air. We're proud that the Omni E35 has earned the Asthma & Allergy Friendly(R) Certification. It's an independent, science-based standard that requires products to prove what they remove through rigorous testing, rather than simply claiming it, and for Anker eufy, that's exactly the bar we want to be measured against," said Frank Zhu, President of Smart Innovations, Anker Innovations.
"People spend 90% of their time indoors and managing exposure to indoor allergens and airway irritants is an important way to control allergy and asthma symptoms," said Kenneth Mendez, president and CEO of AAFA. "By meeting the strict standards of the Asthma & Allergy Friendly(R) Certification program, Anker's eufy Robot Vacuum Omni E35 provides homeowners with another tool that can be a part of effective indoor air quality management."
"As robotic vacuums become a standard part of home cleaning, it's important that consumers have independent, science-based proof that these devices actually reduce allergen exposure. The eufy Robot Vacuum Omni E35 met that standard by demonstrating effective allergen removal while keeping airborne particle levels low during vacuuming and dust-bin emptying, giving people with asthma and allergies clear evidence that this product supports a healthier home," said Dr John McKeon, CEO of Allergy Standards Ltd.
* * *
About the Asthma & Allergy Friendly(R) Certification Program
The Asthma & Allergy Friendly(R) Certification Program is a collaboration between the Asthma and Allergy Foundation of America (AAFA) and Allergy Standards Limited (ASL) that tests and certifies products against strict standards to prove their suitability for people with asthma and allergies. Certified products include air cleaners, air filters, paints, bedding, vacuum cleaners, washing machines, cleaning products, flooring, and more. More information is available at aafa.org/certified.
* * *
About Anker eufy
Anker eufy specializes in AI-driven smart living solutions. Since 2016, we have introduced a wide range of products, from home security systems, robot vacuums, and robot lawn mowers to baby care and personal health devices. Anker Innovations (SZSE: 300866; HKEX: 00668) is a consumer technology company founded in 2011, serving more than 200 million customers across over 180 countries and regions. More information is available at https://www.eufy.com/eufy-robot-vacuum-omni-e35
* * *
Original text here: https://aafa.org/anker-eufy-earns-asthma-allergy-friendly-certification-for-robot-vacuum-omni-e35/
2026 Ballot Guide From the Denver Foundation
DENVER, Colorado, Oct. 24 -- The Denver Foundation issued the following news:
* * *
2026 Ballot Guide from The Denver Foundation
October 22, 2026
Tuesday, Nov. 3, voters will make decisions on state and local issues. This ballot will tie the previous state record of 14 statewide measures. We want to help you get the information you need to make an informed vote.
Below is our ballot guide and links to additional ballot guides from other organizations that we either fund or have a track record of publishing nonpartisan, educational ballot information.
We review ballot issues and take positions ... Show Full Article DENVER, Colorado, Oct. 24 -- The Denver Foundation issued the following news: * * * 2026 Ballot Guide from The Denver Foundation October 22, 2026 Tuesday, Nov. 3, voters will make decisions on state and local issues. This ballot will tie the previous state record of 14 statewide measures. We want to help you get the information you need to make an informed vote. Below is our ballot guide and links to additional ballot guides from other organizations that we either fund or have a track record of publishing nonpartisan, educational ballot information. We review ballot issues and take positionson those that align with our mission, vision, and values, our strategic framework, and our 2026 policy principles. We know there are many issues that our board, staff, and community care deeply about. Our strategic framework and policy principles help guide when to take a position and when not to. We also need to assess our capacity to conduct research and outreach to fully understand the impact on our stakeholders, and that sometimes leads us to not take a position at all. And through our Civic Fabric Fund, we support additional voter education efforts on all state-level and many local-level ballot measures.
Statewide
Oppose 2022 Ballot Measures (1)
Amendment 81: Law Enforcement Reporting Requirements to Federal Authorities
We oppose Amendment 81 because we believe in protecting Coloradans from being racially profiled or targeted by federal authorities. We are also opposing this because we believe in protecting due process rights by making sure no Coloradan is reported to U.S. Immigration and Customs Enforcement (ICE) before a court has found them guilty of a crime and before they have a chance to prove their citizenship.
About: An amendment to the Colorado constitution, requiring certified peace officers employed by a law enforcement agency, correctional officers, and district attorney offices to notify the federal Department of Homeland Security within 72 hours of charging someone with a crime if the person is not believed to be lawfully in the U.S. and is either charged with a violent crime or has a prior felony conviction.
Policy framework alignment: Critical and timely issues. We have backed legislation for the past three years that supports the immigrant community, including state responses to federal actions that diminished protections for immigrants.
Learn more (https://no81.org/).
Oppose 2022 Ballot Measures (1)
Amendment 82: Constitutional Right to Purchase and Sell Natural Gas
We oppose Amendment 82 because it would harm the health and safety of Coloradans and could make it harder for state and local governments to enforce or enact safety and environmental rules that keep our water clean and homes safe. Its passage could also lead to increased costs for consumers.
ABOUT: Adds a new section to the Colorado Constitution that would grant consumers the right to purchase natural gas for cooking or heating in homes or businesses, and for distributors and utilities to sell natural gas to consumers.
Policy framework alignment: Environment and Climate
Learn more (https://no82.org/).
Support 2022 Ballot Measures (1)
Proposition 137: Designate Sporting Goods Sales Tax Revenue for Conservation
We support 137 because it will provide funding, without raising taxes, for wildfire mitigation, outdoor equity programs, and workforce development. We also support this because it will help our state and local governments have the resources needed to adapt to the increasing changes to our climate.
ABOUT: Designates approximately $175 million annually of state sales tax revenue collected from sporting goods and equipment sales as wildfire and conservation revenue.
Policy framework alignment: Environment and Climate, Economic Opportunity
Learn more (https://yesonprop137.com/).
Support 2022 Ballot Measures (1)
Proposition NN: State Public K-12 Education Funding
We support NN because, throughout our history, we've always supported increasing funding for K-12 education. Proposition NN will further increase equitable school funding by allowing the state to invest the revenue it already collects in public education. Funding can be used to increase teachers' salaries, technical training opportunities, and smaller class sizes, without raising taxes or asking Coloradans to pay a dollar more.
ABOUT: Allows the state to retain revenue to support a 2% increase in state education funding over the next decade. This funding would support teacher pay and retention, smaller class sizes, career and technical courses, and school services, among other things.
Policy framework alignment: Youth Well-Being
Learn more (https://www.yesforcoloradokids.com/).
Local: Aurora
Support 2022 Ballot Measures (1)
Aurora: Ballot Issue 3A: Dedicated Sales Tax for Community Facilities
We support this because it will fund the renovation and construction of recreation centers and libraries across Aurora. These vital community resources will help people access resources to help them with school, jobs, and recreational activities.
ABOUT: Designates approximately $105 M through a 0.129% citywide sales and use tax for 30 years to renovate and construct parks, recreation facilities, and libraries.
Policy framework alignment: Economic Opportunity
Learn more (https://www.buildupaurora.com/).
Support 2022 Ballot Measures (1)
Aurora: Ballot Issue 3C: Dedicated Sales Tax for Transportation Infrastructure and Facilities
We support this because this bond invests critically needed dollars into infrastructure and connectivity, ensuring our communities have safe, reliable roads and sidewalks. The selected projects protect pedestrians, build new multimodal transit options, and promote community resilience.
ABOUT: Designates approximately $107.5 M through a 0.129% citywide sales and use tax for 30 years to replace a bridge, construct traffic calming infrastructure, and improve roads, sidewalks, and crosswalks.
Policy framework alignment: Environment and Climate
Learn more (https://www.buildupaurora.com/).
Ballot guides and trackers
There are numerous ballot measures, making it challenging to locate the necessary information to make informed decisions. We hope the resources help you ensure that your registration is active and your vote is informed.
Ballot Guides (as of 10/13)
* Colorado Public Radio (https://www.cpr.org/2026/09/24/vg-2026-colorado-midterm-election-voter-guide/?utm_medium=email&utm_source=lookout&utm_campaign=lookout20260925)
* Colorado Budget Tradeoffs (https://colabnews.co/colorado-tradeoffs/)
* Count me in Colorado (https://countmeincolorado.org/ballot-information/)
* League of Women Voters of Colorado (https://lwvcolorado.org/ballot-issues)
* League of Women Voters of Denver (https://lwvdenver.org/content.aspx?page_id=22&club_id=550279&module_id=362853)
* The Bell Policy Center (https://bellpolicy.org/colorado-ballot-guide-2026/)
* The Denver Post Colorado voter guide (https://www.denverpost.com/2026/10/03/colorado-election-2026-voter-guide-candidates-ballot-measures/)
* Denverite Voter Guide (https://denverite.com/2026/09/25/vg-2026-denver-midterm-election-voter-guide/)
* The Sentinel Aurora Voter Guide (https://sentinelcolorado.com/voter-guide/ballot-questions/co-vote-2026-a-brief-guide-to-pro-and-con-for-the-bevy-of-statewide-ballot-questions/)
* The Women's Foundation of Colorado - The Womanifesto (https://wfco.org/advocacy/ballot-guides-2026/)
* Denver Metro Chamber of Commerce (https://denverchamber.org/denver-metro-chamber-of-commerce-announces-2026-prospective-colorado-ballot-initiative-positions/)
* Progress Now Colorado Education Fund (https://progressnow.co/c3guide26.pdf)
General Resources
* Colorado Blue Book (https://content.leg.colorado.gov/sites/default/files/2026-blue-book-en-accessible.pdf)
* Adams County Election Resources (https://www.adamscountycoelections.gov/2025-coordinated-election/)
* Arapahoe County Election Resources (https://www.arapahoeco.gov/your_county/arapahoevotes/election_resources/index.php)
* Aurora Ballot Guide (https://www.auroragov.org/city_hall/elections/voter_resources)
* Capitol Commons Candidates & Ballot Guide (https://capitolcommons.ai/ballot)
* Colorado Health Foundation Local ballot measures tracker (https://coloradohealth.org/local-ballot-measure-tracker)
* Common Cause Election Protection resources (https://www.commoncause.org/work/election-protection/)
* Check your voter registration (https://www.sos.state.co.us/voter/pages/pub/olvr/findVoterReg.xhtml)
* Denver Ballot Guide (https://denvergov.org/Government/Agencies-Departments-Offices/Agencies-Departments-Offices-Directory/Denver-Clerk-and-Recorder/Elections-Division/Upcoming-Elections)
* Denver Decides candidate forum (https://www.denvergov.org/Government/Elections/Denver-Decides)
* Denver Election Resources (https://denvergov.org/Government/Agencies-Departments-Offices/Agencies-Departments-Offices-Directory/Denver-Clerk-and-Recorder/Elections-Division/Upcoming-Elections)
Supporting voter engagement
Another way we support voter education and engagement on ballot measures is by funding nonprofit organizations to educate and activate voters during the municipal and statewide elections. Learn more about this year's grantees and their work this election here.
You, too, can support this work by giving to the Civic Fabric Fund.
* * *
Original text here: https://denverfoundation.org/2026/10/2026-ballot-guide/
* * *
2026 Ballot Guide from The Denver Foundation
October 22, 2026
Tuesday, Nov. 3, voters will make decisions on state and local issues. This ballot will tie the previous state record of 14 statewide measures. We want to help you get the information you need to make an informed vote.
Below is our ballot guide and links to additional ballot guides from other organizations that we either fund or have a track record of publishing nonpartisan, educational ballot information.
We review ballot issues and take positions ... Show Full Article DENVER, Colorado, Oct. 24 -- The Denver Foundation issued the following news: * * * 2026 Ballot Guide from The Denver Foundation October 22, 2026 Tuesday, Nov. 3, voters will make decisions on state and local issues. This ballot will tie the previous state record of 14 statewide measures. We want to help you get the information you need to make an informed vote. Below is our ballot guide and links to additional ballot guides from other organizations that we either fund or have a track record of publishing nonpartisan, educational ballot information. We review ballot issues and take positionson those that align with our mission, vision, and values, our strategic framework, and our 2026 policy principles. We know there are many issues that our board, staff, and community care deeply about. Our strategic framework and policy principles help guide when to take a position and when not to. We also need to assess our capacity to conduct research and outreach to fully understand the impact on our stakeholders, and that sometimes leads us to not take a position at all. And through our Civic Fabric Fund, we support additional voter education efforts on all state-level and many local-level ballot measures.
Statewide
Oppose 2022 Ballot Measures (1)
Amendment 81: Law Enforcement Reporting Requirements to Federal Authorities
We oppose Amendment 81 because we believe in protecting Coloradans from being racially profiled or targeted by federal authorities. We are also opposing this because we believe in protecting due process rights by making sure no Coloradan is reported to U.S. Immigration and Customs Enforcement (ICE) before a court has found them guilty of a crime and before they have a chance to prove their citizenship.
About: An amendment to the Colorado constitution, requiring certified peace officers employed by a law enforcement agency, correctional officers, and district attorney offices to notify the federal Department of Homeland Security within 72 hours of charging someone with a crime if the person is not believed to be lawfully in the U.S. and is either charged with a violent crime or has a prior felony conviction.
Policy framework alignment: Critical and timely issues. We have backed legislation for the past three years that supports the immigrant community, including state responses to federal actions that diminished protections for immigrants.
Learn more (https://no81.org/).
Oppose 2022 Ballot Measures (1)
Amendment 82: Constitutional Right to Purchase and Sell Natural Gas
We oppose Amendment 82 because it would harm the health and safety of Coloradans and could make it harder for state and local governments to enforce or enact safety and environmental rules that keep our water clean and homes safe. Its passage could also lead to increased costs for consumers.
ABOUT: Adds a new section to the Colorado Constitution that would grant consumers the right to purchase natural gas for cooking or heating in homes or businesses, and for distributors and utilities to sell natural gas to consumers.
Policy framework alignment: Environment and Climate
Learn more (https://no82.org/).
Support 2022 Ballot Measures (1)
Proposition 137: Designate Sporting Goods Sales Tax Revenue for Conservation
We support 137 because it will provide funding, without raising taxes, for wildfire mitigation, outdoor equity programs, and workforce development. We also support this because it will help our state and local governments have the resources needed to adapt to the increasing changes to our climate.
ABOUT: Designates approximately $175 million annually of state sales tax revenue collected from sporting goods and equipment sales as wildfire and conservation revenue.
Policy framework alignment: Environment and Climate, Economic Opportunity
Learn more (https://yesonprop137.com/).
Support 2022 Ballot Measures (1)
Proposition NN: State Public K-12 Education Funding
We support NN because, throughout our history, we've always supported increasing funding for K-12 education. Proposition NN will further increase equitable school funding by allowing the state to invest the revenue it already collects in public education. Funding can be used to increase teachers' salaries, technical training opportunities, and smaller class sizes, without raising taxes or asking Coloradans to pay a dollar more.
ABOUT: Allows the state to retain revenue to support a 2% increase in state education funding over the next decade. This funding would support teacher pay and retention, smaller class sizes, career and technical courses, and school services, among other things.
Policy framework alignment: Youth Well-Being
Learn more (https://www.yesforcoloradokids.com/).
Local: Aurora
Support 2022 Ballot Measures (1)
Aurora: Ballot Issue 3A: Dedicated Sales Tax for Community Facilities
We support this because it will fund the renovation and construction of recreation centers and libraries across Aurora. These vital community resources will help people access resources to help them with school, jobs, and recreational activities.
ABOUT: Designates approximately $105 M through a 0.129% citywide sales and use tax for 30 years to renovate and construct parks, recreation facilities, and libraries.
Policy framework alignment: Economic Opportunity
Learn more (https://www.buildupaurora.com/).
Support 2022 Ballot Measures (1)
Aurora: Ballot Issue 3C: Dedicated Sales Tax for Transportation Infrastructure and Facilities
We support this because this bond invests critically needed dollars into infrastructure and connectivity, ensuring our communities have safe, reliable roads and sidewalks. The selected projects protect pedestrians, build new multimodal transit options, and promote community resilience.
ABOUT: Designates approximately $107.5 M through a 0.129% citywide sales and use tax for 30 years to replace a bridge, construct traffic calming infrastructure, and improve roads, sidewalks, and crosswalks.
Policy framework alignment: Environment and Climate
Learn more (https://www.buildupaurora.com/).
Ballot guides and trackers
There are numerous ballot measures, making it challenging to locate the necessary information to make informed decisions. We hope the resources help you ensure that your registration is active and your vote is informed.
Ballot Guides (as of 10/13)
* Colorado Public Radio (https://www.cpr.org/2026/09/24/vg-2026-colorado-midterm-election-voter-guide/?utm_medium=email&utm_source=lookout&utm_campaign=lookout20260925)
* Colorado Budget Tradeoffs (https://colabnews.co/colorado-tradeoffs/)
* Count me in Colorado (https://countmeincolorado.org/ballot-information/)
* League of Women Voters of Colorado (https://lwvcolorado.org/ballot-issues)
* League of Women Voters of Denver (https://lwvdenver.org/content.aspx?page_id=22&club_id=550279&module_id=362853)
* The Bell Policy Center (https://bellpolicy.org/colorado-ballot-guide-2026/)
* The Denver Post Colorado voter guide (https://www.denverpost.com/2026/10/03/colorado-election-2026-voter-guide-candidates-ballot-measures/)
* Denverite Voter Guide (https://denverite.com/2026/09/25/vg-2026-denver-midterm-election-voter-guide/)
* The Sentinel Aurora Voter Guide (https://sentinelcolorado.com/voter-guide/ballot-questions/co-vote-2026-a-brief-guide-to-pro-and-con-for-the-bevy-of-statewide-ballot-questions/)
* The Women's Foundation of Colorado - The Womanifesto (https://wfco.org/advocacy/ballot-guides-2026/)
* Denver Metro Chamber of Commerce (https://denverchamber.org/denver-metro-chamber-of-commerce-announces-2026-prospective-colorado-ballot-initiative-positions/)
* Progress Now Colorado Education Fund (https://progressnow.co/c3guide26.pdf)
General Resources
* Colorado Blue Book (https://content.leg.colorado.gov/sites/default/files/2026-blue-book-en-accessible.pdf)
* Adams County Election Resources (https://www.adamscountycoelections.gov/2025-coordinated-election/)
* Arapahoe County Election Resources (https://www.arapahoeco.gov/your_county/arapahoevotes/election_resources/index.php)
* Aurora Ballot Guide (https://www.auroragov.org/city_hall/elections/voter_resources)
* Capitol Commons Candidates & Ballot Guide (https://capitolcommons.ai/ballot)
* Colorado Health Foundation Local ballot measures tracker (https://coloradohealth.org/local-ballot-measure-tracker)
* Common Cause Election Protection resources (https://www.commoncause.org/work/election-protection/)
* Check your voter registration (https://www.sos.state.co.us/voter/pages/pub/olvr/findVoterReg.xhtml)
* Denver Ballot Guide (https://denvergov.org/Government/Agencies-Departments-Offices/Agencies-Departments-Offices-Directory/Denver-Clerk-and-Recorder/Elections-Division/Upcoming-Elections)
* Denver Decides candidate forum (https://www.denvergov.org/Government/Elections/Denver-Decides)
* Denver Election Resources (https://denvergov.org/Government/Agencies-Departments-Offices/Agencies-Departments-Offices-Directory/Denver-Clerk-and-Recorder/Elections-Division/Upcoming-Elections)
Supporting voter engagement
Another way we support voter education and engagement on ballot measures is by funding nonprofit organizations to educate and activate voters during the municipal and statewide elections. Learn more about this year's grantees and their work this election here.
You, too, can support this work by giving to the Civic Fabric Fund.
* * *
Original text here: https://denverfoundation.org/2026/10/2026-ballot-guide/